Faruk is a life sciences professional with extensive experience addressing a broad range of strategic issues, including corporate development, portfolio planning, and launch excellence. Prior to joining EVERSANA MANAGEMENT CONSULTING he helped clients apply advanced analytic software technologies to draw unique insights from clinical and commercial data and focused on shaping and executing strategic initiatives for large- and mid-cap life sciences companies.
In addition to being a strategic advisor, Faruk has contributed to entrepreneurial efforts, developing products in both the therapeutic and medical device spaces. He has authored a number of articles that have helped companies consider novel approaches to developing and commercializing their products. He has shared unique perspectives on how companies can adapt their commercial models to an evolving healthcare ecosystem and offered insights on how organizations can rethink the development and integration of analytic capabilities to inform strategic decisions.
Faruk holds an MBA from Harvard Business School and a BS in electrical engineering from Northwestern University.
Articles by Faruk Abdullah
Optimizing Product Commercialization in Today’s IDN Environment
Traditional sales models that rely solely on prescriber outreach or consumer advertising are no longer effective. With nearly 70% of U.S. physicians employed by Integrated Delivery Networks (IDNs), the way therapies are evaluated, approved, and accessed has fundamentally changed. For life sciences companies, understanding the key stakeholders and decision-making processes within each IDN is critical […]
Escaping the Chronic Microcap Trap: How Launching Alone Is the Only Option for Growth
As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have on their current and future market valuation. The question is this: How much of a premium does the market […]
Capital Efficient Commercialization: A New Model for Success
In today’s fiscal environment, efficient capital allocation is crucial for success. Biopharma companies can take advantage of new approaches to commercialization to dramatically reduce the capital burden to launch their products. Building Your Own Commercial Infrastructure Is a Waste of Capital The technology, infrastructure, and full-time staff required for a successful launch can drain millions […]
Boosting Pharma Efficiency: A New Model for Asset Value Retention
In the pharmaceutical industry, maintaining asset value is challenging. Traditionally, companies either licensed their products or built their own commercial setup, each option with its own risks. But what if there were a powerful alternative that boosts efficiency, saves costs, leverages multi-brand expertise, and maximizes revenue potential and asset value—all without the hassle of complex […]
The Path to Maximizing Revenue: How to Simplify Pharmaceutical Commercialization and Find Optimum Success
For pharmaceutical manufacturers, achieving optimal revenue in a competitive landscape is a multifaceted challenge that requires strategic foresight and meticulous execution. Small and emerging biotech companies often face significant hurdles in reaching maximum commercial success. In this blog, we explore the critical factors that influence revenue maximization and why companies must adopt a forward-thinking, integrated […]
IDN Trends, Insights and Strategies Every Manufacturer Should Know
In this latest webinar, hear from three industry experts as the delve into the intricacies of integrated delivery networks (IDNs) and how they are transforming the healthcare landscape. EVERSANA’s Faruk Abdullah and Krista Pinto, and Matthew Wilkins from G1 Therapeutics provide a comprehensive overview of the current trends and future direction of healthcare, particularly the […]
M&A and BD&L Outlook and Perspectives on Commercial Due Diligence
In this webinar, industry leaders Faruk Abdullah, Jakub Pijewski, PhD, and Yao Zhang, PhD, delve into the dynamic world of M&A, BD&L, and Commercial Due Diligence (CDD) in the pharmaceutical and biotech sectors. Gain valuable insights into: Current perspectives on deal-making trends The heightened importance of CDD Best practices and risk mitigation techniques for optimizing CDD […]